ReviewExpert opinion on investigational drugs2020

Glucagon-like peptide-1 (GLP-1)-based receptor agonists as a treatment for Parkinson's disease.

Elliot J Glotfelty et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.